Updated Sep 10, 8:32 PM · 60 sources analyzed
Key Takeaways
Abivax's paired UC Phase 3 trials ABTECT-1 and ABTECT-2 are complete; efficacy data pending and will define the company's competitive position.
MoonLake's sonelokimab Phase 2 in hidradenitis suppurativa completed; data readout is the next major inflection for this mid-cap immunology company.
Today's sources are dominated by registry status changes with zero efficacy disclosures — no material clinical wins or failures are confirmed today.
🏆 Winner
MoonLake Immunotherapeutics — Phase 2 HS trial completion positions them for a near-term data readout in a high-value dermatology indication with limited competition.
📉 Loser
Abivax — both pivotal UC trials are complete but data remain undisclosed, creating uncertainty in a crowded indication where time-to-data matters for partnering and financing.
🔭 Watch Next
MoonLake and Abivax both need to disclose Phase 2 and Phase 3 efficacy data, respectively, likely at major GI and dermatology congresses in Q4 2026 — those readouts will be the first real signals from today's completed registries.
Abivax UC Phase 3 trials ABTECT-1 and ABTECT-2 now complete
Abivax has completed both ABTECT-1 and ABTECT-2, its paired Phase 3 induction trials evaluating ABX464 (obefazimod) at 25 mg and 50 mg daily versus placebo in moderately-to-severely active ulcerative colitis. Registry completion status alone carries no efficacy signal — full data have not been disclosed in today's sources, and investors will need to see whether remission rates differentiate ABX464 from the crowded IL-inhibitor and S1P field. The UC market remains one of the most competitive in gastroenterology, and the outcome of these trials will determine whether Abivax has a credible path to NDA submission or needs a partnering event to survive.
ClinicalTrials.gov ↗Abivax S.A.
ABX464 (obefazimod) in Ulcerative Colitis (moderate-to-severe)
Both ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) are now marked Completed on ClinicalTrials.gov. These multicenter, randomized, placebo-controlled studies evaluated ABX464 at 25 mg and 50 mg QD for induction of clinical remission. Full efficacy and safety data have not yet been released in today's sources.
Why it matters
Registry completion of both pivotal trials is a process milestone, not a verdict — the investment thesis lives or dies on remission and endoscopic improvement rates relative to competitors like ozanimod, upadacitinib, and mirikizumab. Abivax will need to show clinically meaningful absolute remission benefits, not just statistical significance, to attract a partner or justify standalone advancement.
What to watch
Watch for Abivax to present or publish ABTECT-1 and ABTECT-2 efficacy data at a major GI congress such as UEG Week (October 2026) or ECCO, which will be the first real read on whether ABX464 can compete in a crowded field.
MoonLake Immunotherapeutics AG
Sonelokimab in Hidradenitis Suppurativa (moderate-to-severe)
The Phase 2 study evaluating sonelokimab (a nanobody targeting IL-17A and IL-17F simultaneously) versus placebo in moderate-to-severe hidradenitis suppurativa (NCT05322473) is now marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released in today's sources.
Why it matters
MoonLake has been building its HS program alongside its psoriatic arthritis data, and this completion sets up the company's next inflection point — the data readout will tell the market whether sonelokimab's dual mechanism translates to a deeper or more durable response than single-target IL-17 agents. The HS readout is arguably more commercially significant than the PsA program given the unmet need and pricing dynamics.
What to watch
Watch for MoonLake to disclose Phase 2 HS data at a dermatology or rheumatology conference in late 2026, which will determine whether the company advances sonelokimab into a Phase 3 HS program.
EIP Pharma Inc.
Neflamapimod in Dementia with Lewy Bodies (DLB)
The RewinD-LB Phase 2 study (NCT05869669) evaluating neflamapimod in patients with dementia with Lewy bodies — targeting improvement in verbal learning, problem solving, and memory — is now marked Completed on ClinicalTrials.gov. No efficacy or safety results have been disclosed in today's sources.
Why it matters
EIP Pharma has been positioning neflamapimod as a synaptic rescue strategy in DLB, and Phase 2 completion sets up what could be the most clinically meaningful near-term data readout in the DLB space. Investors in Alzheimer's and neurodegeneration adjacencies should track whether the cognitive endpoint data support a Phase 3 power calculation.
What to watch
Watch for EIP Pharma to release topline RewinD-LB data at a neurology conference such as CTAD or the Society for Neuroscience annual meeting in late 2026, which would be the pivotal signal for whether neflamapimod advances in DLB.
Crinetics Pharmaceuticals Inc.
Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia (classic CAH)
The TouCAHn Phase 2 open-label sequential dose cohort study (NCT05907291) evaluating atumelnant's safety, efficacy, and pharmacokinetics in classic congenital adrenal hyperplasia is now marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released in today's sources.
Why it matters
With crinecerfont now on the market, Crinetics needs atumelnant data to demonstrate a clear differentiating profile — whether in hormonal control, tolerability, or dosing convenience — to justify continued investment in a suddenly more competitive CAH landscape. The company's commercial prospects in this space depend heavily on head-to-head differentiation potential.
What to watch
Watch for Crinetics to present TouCAHn data at ENDO 2027 or in a peer-reviewed publication in early 2027, which will define whether atumelnant has a viable path in a market now shaped by crinecerfont.
Both ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) are now marked Completed on ClinicalTrials.gov. These multicenter, randomized, placebo-controlled studies evaluated ABX464 at 25 mg and 50 mg QD for induction of clinical remission. Full efficacy and safety data have not yet been released in today's sources.
Why it matters
UC is one of the most overcrowded indications in biopharma; without efficacy data, it is impossible to assess whether ABX464 offers a differentiated profile versus approved biologics and small molecules.
Analysis
Registry completion of both pivotal trials is a process milestone, not a verdict — the investment thesis lives or dies on remission and endoscopic improvement rates relative to competitors like ozanimod, upadacitinib, and mirikizumab. Abivax will need to show clinically meaningful absolute remission benefits, not just statistical significance, to attract a partner or justify standalone advancement.
What to watch
Watch for Abivax to present or publish ABTECT-1 and ABTECT-2 efficacy data at a major GI congress such as UEG Week (October 2026) or ECCO, which will be the first real read on whether ABX464 can compete in a crowded field.
The Phase 2 study evaluating sonelokimab (a nanobody targeting IL-17A and IL-17F simultaneously) versus placebo in moderate-to-severe hidradenitis suppurativa (NCT05322473) is now marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released in today's sources.
Why it matters
Hidradenitis suppurativa is a high-value dermatology indication with limited approved options; sonelokimab's dual IL-17A/F mechanism could be differentiated from secukinumab and bimekizumab if Phase 2 data show durable HiSCR response rates.
Analysis
MoonLake has been building its HS program alongside its psoriatic arthritis data, and this completion sets up the company's next inflection point — the data readout will tell the market whether sonelokimab's dual mechanism translates to a deeper or more durable response than single-target IL-17 agents. The HS readout is arguably more commercially significant than the PsA program given the unmet need and pricing dynamics.
What to watch
Watch for MoonLake to disclose Phase 2 HS data at a dermatology or rheumatology conference in late 2026, which will determine whether the company advances sonelokimab into a Phase 3 HS program.
The RewinD-LB Phase 2 study (NCT05869669) evaluating neflamapimod in patients with dementia with Lewy bodies — targeting improvement in verbal learning, problem solving, and memory — is now marked Completed on ClinicalTrials.gov. No efficacy or safety results have been disclosed in today's sources.
Why it matters
DLB has no approved disease-modifying therapies; a positive Phase 2 signal for neflamapimod, a p38alpha MAP kinase inhibitor, would be notable in a neurodegenerative indication that has seen repeated failures.
Analysis
EIP Pharma has been positioning neflamapimod as a synaptic rescue strategy in DLB, and Phase 2 completion sets up what could be the most clinically meaningful near-term data readout in the DLB space. Investors in Alzheimer's and neurodegeneration adjacencies should track whether the cognitive endpoint data support a Phase 3 power calculation.
What to watch
Watch for EIP Pharma to release topline RewinD-LB data at a neurology conference such as CTAD or the Society for Neuroscience annual meeting in late 2026, which would be the pivotal signal for whether neflamapimod advances in DLB.
The TouCAHn Phase 2 open-label sequential dose cohort study (NCT05907291) evaluating atumelnant's safety, efficacy, and pharmacokinetics in classic congenital adrenal hyperplasia is now marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released in today's sources.
Why it matters
CAH is a rare endocrine condition with limited treatment options beyond glucocorticoid replacement, and Crinetics is competing with Neurocrine's crinecerfont — which received FDA approval in late 2024 — making the atumelnant Phase 2 data critical for competitive differentiation.
Analysis
With crinecerfont now on the market, Crinetics needs atumelnant data to demonstrate a clear differentiating profile — whether in hormonal control, tolerability, or dosing convenience — to justify continued investment in a suddenly more competitive CAH landscape. The company's commercial prospects in this space depend heavily on head-to-head differentiation potential.
What to watch
Watch for Crinetics to present TouCAHn data at ENDO 2027 or in a peer-reviewed publication in early 2027, which will define whether atumelnant has a viable path in a market now shaped by crinecerfont.
The randomized, quadruple-masked, multi-center Phase 2 trial with open-label extension evaluating BPL-003 efficacy and safety in treatment-resistant depression (NCT05870540) is now marked Completed on ClinicalTrials.gov. No efficacy or safety results have been disclosed in today's sources.
Why it matters
TRD is a high-priority space following the FDA approval of esketamine and ongoing Phase 3 programs for psilocybin-based therapies; a differentiated psychedelic-adjacent compound like BPL-003 could attract significant BD interest if data are compelling.
Analysis
Beckley Psytech's completion of this blinded Phase 2 puts them in the queue of psychedelic-adjacent companies that will need to show meaningful remission rates and durability — not just statistical separation from placebo — to justify advancing in a regulatory environment that is still defining what constitutes a meaningful TRD benefit. The open-label extension data will be as important as the core trial for understanding durability.
What to watch
Watch for Beckley Psytech to disclose BPL-003 Phase 2 topline data at a psychiatry conference or via press release in late 2026, which will be the first public signal on whether the compound warrants Phase 3 investment.
Mesenchymal Stem Cell Infusions for Parkinson's Disease: Phase 2a Trial Completes
A Phase 2a randomized placebo-controlled trial (NCT04506073) evaluating allogeneic bone marrow-derived mesenchymal stem cell infusions to slow Parkinson's disease progression has completed, though no efficacy or safety data are yet publicly disclosed.
Why it matters
If MSC therapy demonstrates a disease-modifying signal in Parkinson's — an indication with zero approved disease-modifying agents — it would validate the allogeneic cell therapy approach in a CNS neurodegenerative indication and open a significant development pathway.
Analysis
The completion of this trial is a logistical milestone in a field that has struggled to conduct rigorous randomized studies of cell therapies in neurodegenerative disease. The data readout will be a bellwether for whether MSC platforms have any traction in Parkinson's, a question that has significant implications for companies developing allogeneic cell products in CNS.
What to watch
Watch for peer-reviewed publication or conference presentation of the Phase 2a MSC Parkinson's data, likely in a neurology journal or at the International Congress of Parkinson's Disease and Movement Disorders, which will determine whether a larger controlled trial is warranted.
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: Phase 2 Study Completes
A Phase 2 trial (NCT04932434) assessing the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety specifically in Parkinson's disease patients has completed at UCSF.
Why it matters
Parkinson's patients with comorbid depression and anxiety represent a distinct and underserved population where standard antidepressants carry significant tolerability issues, making a psilocybin signal here potentially actionable for drug developers targeting the neuropsychiatric Parkinson's phenotype.
Analysis
This feasibility-focused Phase 2 fills an important data gap: whether patients with a neurodegenerative disease can safely undergo psilocybin-assisted therapy. A positive tolerability signal would open the door for larger efficacy studies and could attract interest from companies with psychedelic assets seeking to differentiate in adjacent indications beyond primary MDD or TRD.
What to watch
Watch for the UCSF team to publish results in a peer-reviewed psychiatry or neurology journal in 2026–2027, which will indicate whether the safety and feasibility profile supports an IND-enabled Phase 2b in the Parkinson's neuropsychiatric indication.
Novartis Antimalarial Combination INE963 Plus Cipargamin Completes Phase 2 Cohort
Cohort B1 of a Novartis platform Phase 2 study (NCT07811882) evaluating the combination of INE963 and cipargamin in uncomplicated Plasmodium falciparum malaria has completed, with no efficacy data yet disclosed in today's sources.
Why it matters
Combining two novel mechanism agents targeting distinct parasite pathways is a central strategy for overcoming artemisinin resistance, and a clean safety and efficacy readout from this combination could inform regulatory pathways for next-generation antimalarials in endemic regions.
Analysis
Novartis has been systematic in advancing novel antimalarial combinations through its platform study design, which allows efficient multi-cohort evaluation. The completion of this cohort signals that Novartis is actively building the evidence base to support regulatory submissions in a disease area where WHO urgently needs new treatment options, and the data will matter for global health funders and policy makers as much as for investors.
What to watch
Watch for Novartis to present INE963 plus cipargamin efficacy and safety data at the American Society of Tropical Medicine and Hygiene annual meeting in late 2026, which will determine whether the combination advances to a registration-enabling study.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.